Neurotech / BCI · Updated 6 August 2026
Precision Neuroscience's minimally-invasive brain-computer interface won early FDA clearance milestones, supporting an estimated ~$500M valuation. As a Neuralink alternative it benefits from BCI enthusiasm, drawing selective secondary interest at an early clinical stage.
Secondary Flow is a research tool, not a broker-dealer or a marketplace, so it does not execute transactions in Precision Neuroscience or any other private company. Private-company shares typically change hands through a company-approved tender offer, a direct transfer subject to the company's right of first refusal, or a regulated secondary marketplace, and most transfers require issuer consent. Secondary Flow tracks the resulting prices.
Not investment advice. Figures are compiled from publicly available sources believed reliable but not independently verified, and provided “as is” without warranty. Secondary-market prices are indications, not executed trades. Secondary Flow is an independent research tool, not a broker-dealer or investment adviser; company names and trademarks belong to their respective owners (no affiliation or endorsement implied).